The U.S. Food and Drug Administration on Thursday approved BioMarin Pharmaceutical's BMRN.O gene therapy for hemophilia A, the company said, giving patients with the inherited bleeding disorder an option to reduce regular blood infusions.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$267.92 |
Change
-1.640(0.61%) |
Mkt cap ! $129.7B | |||
| Open | High | Low | Value | Volume |
| $269.56 | $270.42 | $267.15 | $252.9M | 957.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 879 | $267.91 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $268.98 | 120 | 1 |
View Market Depth
| Last trade - 16.10pm 25/07/2025 (20 minute delay) ? |
| CSL (ASX) Chart |